| Ms Sharon Barbara Drakos, RN, APRN | |
|
5 S Main St, Branford, CT 06405-3800 | |
| (203) 488-1577 | |
| (203) 481-1814 |
| Full Name | Ms Sharon Barbara Drakos |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Adult Health |
| Location | 5 S Main St, Branford, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215051859 | NPI | - | NPPES |
| 400000446CT04 | Other | CT | ANTHEM INSURANCE PIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | 000446 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Sharon Barbara Drakos, RN, APRN 26 Totoket Rd, Branford, CT 06405-6400 Ph: (203) 488-2227 | Ms Sharon Barbara Drakos, RN, APRN 5 S Main St, Branford, CT 06405-3800 Ph: (203) 488-1577 |
News Archive
Researchers at the University of Nebraska Medical Center have identified a key cell signaling pathway that drives the devastating muscle loss, or cachexia, suffered by many cancer patients.
African-American women with lower socio-economic status have an increased risk of depressive disorders, yet they rarely seek out antidepressants or psychotherapy because of negative attitudes and stigma associated with conventional mental health treatments.
Genetic polymorphisms associated with cancer progression lead to variations in gene expression and may serve as prognostic markers for lung cancer. Researchers at the Hiroshima University and Saitama Medical University found that in patients with lung cancer, a single nucleotide polymorphism (SNP) may regulate gene and protein expression and be associated with poor prognosis.
t first glance, America is making great strides toward a medical and cultural shift in its approach to end-of-life care: More and more providers are recognizing the benefits of hospice, more people are dying at home, and many health care organizations are institutionalizing the discussions between providers and patients that would help patients formalize their wishes for end-of-life care through an advance directive. But pull up the curtain on these statistics, and the drama that unfolds tells a very different story. End-of-life care continues to be characterized by aggressive medical intervention and runaway costs (Adamopoulos, 6/3).
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection.
› Verified 9 days ago
Prof. Joan Kearney, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 94 N Branford Rd, Branford, CT 06405 Phone: 203-483-6922 | |
Joanne Marie Iennaco, APRN Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 1090 Main St, Branford, CT 06405 Phone: 203-285-5399 |